Kurser indlæses...
Prognose
Analytikernes gennemsnitlige kursmål er 20,53 € (+21,48 %). Medianen er 17,45 € (+3,25 %).
| Køb |
24 |
| Behold |
15 |
| Sælg |
0 |
Nyheder Til nyhedsfeedet
Tandem Diabetes relies on pharmacy model, Mobi‑Patch and international direct sales for growth
Tandem Diabetes unveiled a long-term growth plan that includes a pharmacy-based pay-as-you-go model in the US, broader rollout of the tubeless Mobi‑Patch pump in the second half of 2026, and expansion of direct sales activities in selected international markets. The new US model is intended to remove the initial cost barrier for patients and bring up to 80% of US sales through pharmacies; internationally, the company expects higher prices and better follow-on care via direct business. New patient starts stalled in the second quarter, but Tandem expects growth in the second half of the year driven by product dynamics, seasonal demand and additional PBM coverage. At the same time, the company is advancing automation projects, including development toward a fully closed‑loop insulin system and integration of existing CGM technologies. » Mere på de.investing.com
Tandem Diabetes Care beats profit forecasts, shares fall after slight revenue miss
Tandem Diabetes Care reported adjusted EPS of -$0.31 for Q2, beating the analyst estimate of -$0.33, while revenue of $254.6 million missed estimates only slightly. Gross margin rose to 57% and adjusted EBITDA margin reached 3%, marking the fourth consecutive positive quarter. Management reaffirmed the full-year outlook, highlighted record shipments and progress in pharmacy distribution, and expects approval of Mobi Tubeless in the second half of 2026. The stock fell about 4.1% in regular trading and recovered slightly in after-hours trading. » Mere på de.investing.com
Tandem Diabetes Care lags after reimbursement shift clouds near-term revenue
Meridian Small Cap Growth Fund said Tandem Diabetes Care underperformed in Q2 as its transition to a pharmacy-based, pay-as-you-go reimbursement model reduced near-term revenue visibility and second-quarter guidance missed expectations. The fund noted added caution from a new competing patch-pump entrant and that Tandem’s lower-beta profile lagged in a market favoring high-beta names. Meridian remains invested, citing the company’s differentiated pump technology, growing installed base and recurring supply revenue, and views the reimbursement change as a long-term positive. » Mere på finance.yahoo.com
Historisk udbytte Udbytte
Alle nøgletal for udbytte Alle nøgletalVirksomhedstal
| (EUR) | juni 2026 | YoY |
|---|---|---|
| Omsætning | 223,05 mio. | 9,23 % |
| Bruttofortjeneste | 126,86 mio. | 18,81 % |
| Nettoresultat | -18,55 mio. | 58,28 % |
| EBITDA | -12,04 mio. | 72,08 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 1,18 mia. € |
Antal aktier | 69,58 mio. |
Højeste/laveste i 52 uger | 26,53 € - 10,97 € |
| Udbytte | Nej |
Beta | 1,66 |
P/E (PE Ratio) | -20,35 |
PEG (PEG Ratio) | -0,19 |
K/I (PB Ratio) | 9,91 |
P/S (PS Ratio) | 1,26 |
Virksomhedsprofil
Tandem Diabetes Care, Inc., en medicinsk udstyrsvirksomhed, designer, udvikler og kommercialiserer forskellige produkter til personer med insulinafhængig diabetes i USA og internationalt. Selskabets flagskibsprodukt er t:slim X2-insulinpumpesystemet, en pumpeplatform bestående af t:slim X2-pumpen, dens engangsinsulinpatron på 300 enheder og et infusionssæt. Det tilbyder også t:slim X2 med Basal-IQ og Control IQ-teknologi; t:slim X2 med G5-integration; og Tandem Device Updater, et værktøj, der gør det muligt for brugerne at opdatere pumpens software. Derudover tilbyder selskabet t:connect, en webbaseret applikation til datahåndtering, som giver en visuel måde at vise data fra diabetesbehandlingen fra pumpen, kontinuerlig glukosemåling og understøttede blodglukosemålere på for brugere, deres plejepersonale og deres sundhedsudbydere; og Sugarmate, en mobilapp til personer med diabetes, der anvender insulin. Selskabet har udviklings- og kommercialiseringsaftaler med Dexcom, Inc. og Abbott Laboratories. Selskabet var tidligere kendt som Phluid Inc. og skiftede navn til Tandem Diabetes Care, Inc. i januar 2008. Tandem Diabetes Care, Inc. blev stiftet i 2006 og har hovedkontor i San Diego, Californien.
| Navn | Tandem Diabetes Care |
| CEO | John F. Sheridan |
| Hjemsted | San Diego,
ca USA |
| Websted | |
| Sektor | Sundhed |
| Branche | Sundhedsudstyr og -produkter |
| Børsnotering | 14.11.2013 |
| Medarbejdere | 2.500 |
Tickersymboler
| Børs | Symbol |
|---|---|
NASDAQ | TNDM |
Frankfurt | TD5A.F |
Düsseldorf | TD5A.DU |
London | 0M0F.L |
München | TD5A.MU |
